IBI302

BIOLOGICAL3 trials

Sponsors

Innovent Biologics (Suzhou) Co. Ltd., Innovent Biologics Technology Limited (Shanghai R&D Center)

Conditions

Diabetic Macular OedemaNeovascular Age-related Macular Degeneration

Phase 1

A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular Degeneration

CompletedNCT03814291

Innovent Biologics (Suzhou) Co. Ltd.Neovascular Age-related Macular Degeneration

Start: 2019-04-15End: 2020-04-10Updated: 2025-04-17

Phase 2

A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema（DME）

Active, not recruitingNCT06908876

Innovent Biologics Technology Limited (Shanghai R&D Center)Diabetic Macular Oedema

Start: 2025-04-24End: 2027-02-28Updated: 2026-05-27

Phase 3

A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD

Active, not recruitingNCT05972473

Innovent Biologics (Suzhou) Co. Ltd.Neovascular Age-related Macular Degeneration

Start: 2023-09-21End: 2027-04-30Updated: 2025-03-13

Related Papers

Targeting C3b/C4b and VEGF with a bispecific fusion protein optimized for neovascular age-related macular degeneration therapy

Science Translational Medicine2022-06-0156 citations